Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti-Epileptic Drugs,Anti-Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Lab-based analysis
    • 2.2.1.3 Approach 3: Drug class-based analysis
    • 2.2.1.4 Approach 4: Presentations of companies and primary interviews
    • 2.2.1.5 Growth forecast
    • 2.2.1.6 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ASSESSMENT
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 STUDY LIMITATIONS
• 2.7 GROWTH RATE ASSUMPTIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW
• 4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SHARE, BY DRUG CLASS AND COUNTRY (2023)
• 4.3 THERAPEUTIC DRUG MONITORING MARKET, BY KEY COUNTRY
• 4.4 THERAPEUTIC DRUG MONITORING MARKET: REGIONAL MIX, 2024-2029
• 4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Importance of therapeutic drug monitoring in organ transplant procedures
    • 5.2.1.2 Use of therapeutic drug monitoring across various therapeutic fields
    • 5.2.1.3 Increasing preference for precision medicine
    • 5.2.1.4 Growing focus on R&D related to therapeutic drug monitoring
    • 5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
    • 5.2.1.6 Increasing prevalence of epilepsy
    • 5.2.1.7 Rising prevalence of cancer
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High capital investments
    • 5.2.2.2 Reluctance of small hospitals to offer therapeutic drug monitoring services
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Significant opportunities in BRICS countries
    • 5.2.3.2 Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring
    • 5.2.3.3 Integration of AI and machine learning
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Alternatives to conventional therapeutic drug monitoring
    • 5.2.4.2 Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries
    • 5.2.4.3 Shortage of skilled professionals
• 5.3 PRICING ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 REGULATORY LANDSCAPE
  • 5.7.1 NORTH AMERICA
    • 5.7.1.1 US
    • 5.7.1.2 Canada
  • 5.7.2 EUROPE
  • 5.7.3 ASIA PACIFIC
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
  • 5.7.4 LATIN AMERICA
  • 5.7.5 MIDDLE EAST
  • 5.7.6 AFRICA
• 5.8 TRADE ANALYSIS
• 5.9 PATENT ANALYSIS
• 5.10 KEY CONFERENCES AND EVENTS IN 2025 AND 2026
• 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGY
    • 5.12.1.1 Enzyme-linked immunosorbent assay
  • 5.12.2 COMPLEMENTARY TECHNOLOGY
    • 5.12.2.1 Liquid chromatography-mass spectrometry
  • 5.12.3 ADJACENT TECHNOLOGY
    • 5.12.3.1 Electrophoresis
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 THREAT OF SUBSTITUTES
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT AND FUNDING SCENARIO
• 5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE (AI) ON THERAPEUTIC DRUG MONITORING MARKET

6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 REPEAT PURCHASES AND HIGH USAGE TO DRIVE MARKET
• 6.3 EQUIPMENT
  • 6.3.1 IMMUNOASSAY ANALYZERS
    • 6.3.1.1 High efficiency to drive adoption
  • 6.3.2 CHROMATOGRAPHY & MS DETECTORS
    • 6.3.2.1 Technological advancements to propel growth
  • 6.3.3 CLINICAL CHEMISTRY ANALYZERS
    • 6.3.3.1 Increasing incidence of chronic and complex diseases to drive market

7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 IMMUNOASSAYS
  • 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS
    • 7.2.1.1 Accurate measurement of target-specific proteins to drive market
  • 7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS
    • 7.2.2.1 Rapid detection time and good specificity to support growth
  • 7.2.3 FLUORESCENCE IMMUNOASSAYS
    • 7.2.3.1 High operability and better sensitivity of FIAs to drive market
  • 7.2.4 COLORIMETRIC IMMUNOASSAYS
    • 7.2.4.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment
  • 7.2.5 OTHER IMMUNOASSAYS
• 7.3 CHROMATOGRAPHY-MS
  • 7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
    • 7.3.1.1 High accuracy to drive demand for LC-MS
  • 7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
    • 7.3.2.1 Drawbacks of GC-MS to challenge market growth
• 7.4 OTHER TECHNOLOGIES

8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS

• 8.1 INTRODUCTION
• 8.2 ANTIEPILEPTIC DRUGS
  • 8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH
• 8.3 ANTIARRHYTHMIC DRUGS
  • 8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND
• 8.4 IMMUNOSUPPRESSANT DRUGS
  • 8.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTATION PROCEDURES TO DRIVE MARKET
• 8.5 ANTIBIOTIC DRUGS
  • 8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND
• 8.6 BRONCHODILATOR DRUGS
  • 8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
• 8.7 PSYCHOACTIVE DRUGS
  • 8.7.1 RISING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH
• 8.8 OTHER DRUGS

9 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA

• 9.1 INTRODUCTION
• 9.2 NEUROLOGICAL DISORDERS
  • 9.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
• 9.3 CARDIOLOGY
  • 9.3.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
• 9.4 INFECTIOUS DISEASES
  • 9.4.1 INCREASING PREVALENCE OF TB AND HEPATITIS TO BOOST DEMAND
• 9.5 ONCOLOGY
  • 9.5.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON PERSONALIZED MEDICINE TO PROPEL MARKET
• 9.6 OTHER THERAPEUTIC AREAS

10 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN

• 10.1 INTRODUCTION
• 10.2 BLOOD
  • 10.2.1 INNOVATIONS IN BLOOD SAMPLING TECHNIQUES TO DRIVE MARKET
• 10.3 SALIVA
  • 10.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET
• 10.4 OTHER SAMPLES

11 THERAPEUTIC DRUG MONITORING MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOSPITAL LABORATORIES
  • 11.2.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS PERFORMED TO DRIVE MARKET
• 11.3 COMMERCIAL & PRIVATE LABORATORIES
  • 11.3.1 EXTENSIVE TEST MENU OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES
• 11.4 OTHER END USERS

12 THERAPEUTIC DRUG MONITORING MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 12.2.2 US
    • 12.2.2.1 Increasing awareness regarding precision medicine to propel market
  • 12.2.3 CANADA
    • 12.2.3.1 Availability of funding for research to offer growth opportunities
• 12.3 EUROPE
• 12.4 EUROPE: MACROECONOMIC OUTLOOK
  • 12.4.1 GERMANY
    • 12.4.1.1 Rising prevalence of chronic medical conditions such as cancer and diabetes to support market growth
  • 12.4.2 UK
    • 12.4.2.1 Increasing cases of chronic diseases to drive market
  • 12.4.3 FRANCE
    • 12.4.3.1 Rising awareness of benefits of therapeutic drug monitoring to accelerate demand
  • 12.4.4 ITALY
    • 12.4.4.1 Rising incidence of cancer to drive demand
  • 12.4.5 SPAIN
    • 12.4.5.1 Adoption of technologically advanced immunoassays to boost market
  • 12.4.6 REST OF EUROPE
• 12.5 ASIA PACIFIC
• 12.6 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 12.6.1 JAPAN
    • 12.6.1.1 High prevalence of chronic diseases and advanced healthcare infrastructure to drive market
  • 12.6.2 CHINA
    • 12.6.2.1 Rising number of organ transplants to boost market
  • 12.6.3 INDIA
    • 12.6.3.1 Rising incidence of cancer to propel market
  • 12.6.4 AUSTRALIA
    • 12.6.4.1 High healthcare expenditure and favorable government initiatives to propel market
  • 12.6.5 REST OF ASIA PACIFIC
• 12.7 LATIN AMERICA
  • 12.7.1 INCREASING BURDEN OF CHRONIC CONDITIONS AND EXPANDING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
  • 12.7.2 LATIN AMERICA: MACROECONOMIC OUTLOOK
• 12.8 MIDDLE EAST & AFRICA
  • 12.8.1 INCREASING NUMBER OF CANCER PATIENTS TO DRIVE MARKET
  • 12.8.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
• 12.9 GCC COUNTRIES
  • 12.9.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
  • 12.9.2 GCC COUNTRIES: MACROECONOMIC OUTLOOK

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 RIGHT TO WIN
• 13.3 STRATEGIES ADOPTED BY KEY PLAYERS
• 13.4 REVENUE ANALYSIS
• 13.5 MARKET SHARE ANALYSIS
• 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS
  • 13.6.1 STARS
  • 13.6.2 EMERGING LEADERS
  • 13.6.3 PERVASIVE PLAYERS
  • 13.6.4 PARTICIPANTS
  • 13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.6.5.1 Company footprint
    • 13.6.5.2 Region footprint
    • 13.6.5.3 Product footprint
    • 13.6.5.4 Technology footprint
    • 13.6.5.5 End-user footprint
• 13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES
  • 13.7.1 PROGRESSIVE COMPANIES
  • 13.7.2 RESPONSIVE COMPANIES
  • 13.7.3 DYNAMIC COMPANIES
  • 13.7.4 STARTING BLOCKS
  • 13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 13.7.5.1 Detailed list of key startups/SMEs
• 13.8 COMPANY VALUATION & FINANCIAL METRICS
  • 13.8.1 FINANCIAL METRICS
  • 13.8.2 COMPANY VALUATION
• 13.9 PRODUCT/BRAND COMPARISON
• 13.10 COMPETITIVE SCENARIO
  • 13.10.1 PRODUCT LAUNCHES
  • 13.10.2 DEALS
  • 13.10.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 ABBOTT
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 MnM view
      • 14.1.1.3.1 Key strengths
      • 14.1.1.3.2 Strategic choices
      • 14.1.1.3.3 Weaknesses and competitive threats
  • 14.1.2 THERMO FISHER SCIENTIFIC INC.
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches
      • 14.1.2.3.2 Deals
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches
      • 14.1.3.3.2 Deals
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 SIEMENS HEALTHINEERS AG
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 DANAHER CORPORATION
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches
      • 14.1.5.3.2 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 BIO-RAD LABORATORIES, INC.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches
      • 14.1.6.3.2 Deals
  • 14.1.7 BIOMERIEUX SA
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
  • 14.1.8 BIOSYNEX SA
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
      • 14.1.8.3.2 Deals
  • 14.1.9 GRIFOLS, S.A.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
  • 14.1.10 EXAGEN INC.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Deals
  • 14.1.11 ARK DIAGNOSTICS, INC.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
  • 14.1.12 R-BIOPHARM AG
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product launches
  • 14.1.13 RANDOX LABORATORIES LTD.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
• 14.2 OTHER PLAYERS
  • 14.2.1 APDIA GROUP
  • 14.2.2 BBI SOLUTIONS
  • 14.2.3 EAGLE BIOSCIENCES, INC.
  • 14.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS
  • 14.2.5 AALTO SCIENTIFIC, LTD.
  • 14.2.6 IMMUNDIAGNOSTIK AG
  • 14.2.7 UTAK
  • 14.2.8 SEKISUI MEDICAL CO., LTD.
  • 14.2.9 DIASYSTEM SCANDINAVIA AB
  • 14.2.10 CAMBRIDGE LIFE SCIENCES LIMITED
  • 14.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
  • 14.2.12 BUHLMANN LABORATORIES AG
  • 14.2.13 SJK GLOBAL, LLC
  • 14.2.14 EPITOPE DIAGNOSTICS, INC.
  • 14.2.15 QED BIOSCIENCE INC.
  • 14.2.16 BODITECH MED INC.
  • 14.2.17 IMMUNODIAGNOSTIC SYSTEMS

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS

List of Tables

• TABLE 1 RISK ASSESSMENT: THERAPEUTIC DRUG MONITORING MARKET
• TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING
• TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
• TABLE 4 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS, BY TYPE
• TABLE 5 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS, BY KEY PLAYER, 2022-2024
• TABLE 6 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS, BY KEY REGION
• TABLE 7 THERAPEUTIC DRUG MONITORING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 IMPORT DATA FOR INSTRUMENTS AND APPARATUS USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2019-2023 (USD MILLION)
• TABLE 13 EXPORT DATA FOR INSTRUMENTS AND APPARATUS USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2019-2023 (USD MILLION)
• TABLE 14 LIST OF CONFERENCES AND EVENTS, 2025-2026
• TABLE 15 THERAPEUTIC DRUG MONITORING MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
• TABLE 17 KEY BUYING CRITERIA FOR END USERS
• TABLE 18 AI APPLICATIONS IN THERAPEUTIC DRUG MONITORING
• TABLE 19 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 20 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 21 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 22 EUROPE: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 23 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 24 DRUGS MONITORED USING ANALYTICAL EQUIPMENT
• TABLE 25 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 26 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 27 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 28 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 29 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 30 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 31 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 32 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 33 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 34 CHROMATOGRAPHY & MS DETECTORS: PRODUCT LAUNCHES, BY COMPANY, 2020-2024
• TABLE 35 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 36 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 37 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 38 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 39 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 40 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 41 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 42 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 43 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 44 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 45 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 46 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 47 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 48 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 49 THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 50 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 51 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 52 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 53 EXAMPLES OF CLIA SYSTEMS
• TABLE 54 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAYS
• TABLE 55 THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 56 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 57 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 58 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 59 LIST OF COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS
• TABLE 60 THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 61 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 62 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 63 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 64 THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 65 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 66 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 67 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 68 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 69 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 70 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 71 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 72 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 73 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 74 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 75 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 76 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 77 THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 79 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 80 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 81 THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 83 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 84 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 85 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 86 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 87 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 88 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 89 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 90 DOSAGE GUIDELINES FOR NEW ANTIEPILEPTIC DRUGS IN ADOLESCENTS AND ADULTS
• TABLE 91 THERAPEUTIC DRUG MONITORING: LIMITATIONS FACED IN NEW ANTIEPILEPTIC DRUGS
• TABLE 92 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 93 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 94 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 95 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 96 CLASSIFICATION OF ANTIARRHYTHMIC THERAPIES
• TABLE 97 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 98 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 99 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 100 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 101 COMMONLY USED IMMUNOSUPPRESSANT DRUGS IN ORGAN TRANSPLANTS
• TABLE 102 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 103 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 104 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 105 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 106 EXAMPLES OF ANTIBIOTIC DRUGS
• TABLE 107 COMPARISON OF DIFFERENT TECHNOLOGIES FOR DETERMINING ANTIMICROBIAL LEVELS IN BIOFLUIDS
• TABLE 108 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 109 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 110 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 111 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 112 EXAMPLES OF BRONCHODILATOR DRUGS
• TABLE 113 THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 114 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 115 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 116 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 117 EXAMPLES OF PSYCHOACTIVE DRUGS
• TABLE 118 THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 119 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 120 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 121 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 122 EXAMPLES OF OTHER DRUGS
• TABLE 123 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 124 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 125 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 126 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 127 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 128 PREVALENCE OF NEUROLOGICAL DISORDERS
• TABLE 129 THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 130 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 131 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 132 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 133 THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 134 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 135 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 136 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 137 THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 138 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 139 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 140 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 141 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2040 (MILLION)
• TABLE 142 THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 143 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 144 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 145 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 146 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 147 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 148 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 149 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 150 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 151 THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 152 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 153 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 154 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 155 THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 156 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 157 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 158 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 159 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 160 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 161 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 162 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 163 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 164 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 165 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 166 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 167 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 168 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 169 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 170 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 171 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 172 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 173 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 174 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 175 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 176 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 177 NORTH AMERICA: KEY MACROINDICATORS
• TABLE 178 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 179 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 180 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 181 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 182 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 183 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 184 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 185 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 186 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 187 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 188 FDA NOVEL DRUG THERAPY APPROVALS FOR 2023
• TABLE 189 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS
• TABLE 190 US: NUMBER OF LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY TESTS, 2022-2029 (MILLION)
• TABLE 191 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 192 US: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 193 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 194 US: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 195 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 196 US: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 197 US: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 198 US: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 199 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 200 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 201 CANADA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 202 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 203 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 204 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 205 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 206 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 207 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 208 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 209 EUROPE: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
• TABLE 210 EUROPE: KEY MACROINDICATORS
• TABLE 211 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 212 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 213 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 214 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 215 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 216 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 217 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 218 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 219 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 220 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 221 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 222 GERMANY: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 223 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 224 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 225 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 226 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 227 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 228 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 229 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 230 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 231 UK: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 232 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 233 UK: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 234 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 235 UK: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 236 UK: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 237 UK: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 238 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 239 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 240 FRANCE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 241 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 242 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 243 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 244 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 245 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 246 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 247 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 248 ITALY: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
• TABLE 249 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 250 ITALY: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 251 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 252 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 253 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 254 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 255 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 256 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 257 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 258 SPAIN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
• TABLE 259 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 260 SPAIN: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 261 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 262 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 263 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 264 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 265 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 266 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 267 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 268 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 269 REST OF EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 270 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 271 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 272 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 273 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 274 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 275 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 276 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 277 ASIA PACIFIC: KEY MACROINDICATORS
• TABLE 278 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 279 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 280 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 281 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 282 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 283 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 284 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 285 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 286 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 287 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 288 JAPAN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
• TABLE 289 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 290 JAPAN: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 291 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 292 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 293 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 294 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 295 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 296 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 297 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 298 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 299 CHINA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 300 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 301 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 302 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 303 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 304 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 305 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 306 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 307 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 308 INDIA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 309 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 310 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 311 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 312 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 313 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 314 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 315 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 316 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 317 AUSTRALIA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 318 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 319 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 320 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 321 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 322 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 323 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 324 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 325 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 326 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 327 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 328 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 329 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 330 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 331 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 332 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 333 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 334 LATIN AMERICA: KEY MACROINDICATORS
• TABLE 335 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 336 LATIN AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 337 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 338 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 339 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 340 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 341 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 342 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 343 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 344 MIDDLE EAST & AFRICA: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045
• TABLE 345 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
• TABLE 346 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 347 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 348 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 349 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 350 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 351 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 352 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 353 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 354 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 355 GCC COUNTRIES: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045
• TABLE 356 GCC COUNTRIES: KEY MACROINDICATORS
• TABLE 357 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 358 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 359 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 360 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 361 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 362 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 363 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 364 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
• TABLE 365 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 366 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2021-NOVEMBER 2024
• TABLE 367 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION
• TABLE 368 THERAPEUTIC DRUG MONITORING MARKET: REGION FOOTPRINT
• TABLE 369 THERAPEUTIC DRUG MONITORING MARKET: PRODUCT FOOTPRINT
• TABLE 370 THERAPEUTIC DRUG MONITORING MARKET: TECHNOLOGY FOOTPRINT
• TABLE 371 THERAPEUTIC DRUG MONITORING MARKET: END-USER FOOTPRINT
• TABLE 372 THERAPEUTIC DRUG MONITORING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 373 THERAPEUTIC DRUG MONITORING MARKET: PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
• TABLE 374 THERAPEUTIC DRUG MONITORING MARKET: DEALS, JANUARY 2021- NOVEMBER 2024
• TABLE 375 THERAPEUTIC DRUG MONITORING MARKET: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
• TABLE 376 ABBOTT: COMPANY OVERVIEW
• TABLE 377 ABBOTT: PRODUCTS OFFERED
• TABLE 378 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 379 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
• TABLE 380 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
• TABLE 381 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 382 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 383 CURRENCY CONVERSION FOR F. HOFFMANN-LA ROCHE LTD.
• TABLE 384 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
• TABLE 385 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2021- OCTOBER 2024
• TABLE 386 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 387 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
• TABLE 388 CURRENCY CONVERSION FOR SIEMENS HEALTHINEERS AG
• TABLE 389 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
• TABLE 390 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021- OCTOBER 2024
• TABLE 391 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 392 DANAHER CORPORATION: COMPANY OVERVIEW
• TABLE 393 DANAHER CORPORATION: PRODUCTS OFFERED
• TABLE 394 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
• TABLE 395 DANAHER CORPORATION: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 396 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 397 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
• TABLE 398 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2021- OCTOBER 2024
• TABLE 399 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 400 BIOMERIEUX SA: COMPANY OVERVIEW
• TABLE 401 CURRENCY CONVERSION FOR BIOMERIEUX SA
• TABLE 402 BIOMERIEUX SA: PRODUCTS OFFERED
• TABLE 403 BIOSYNEX SA: COMPANY OVERVIEW
• TABLE 404 CURRENCY CONVERSION FOR BIOSYNEX SA
• TABLE 405 BIOSYNEX SA: PRODUCTS OFFERED
• TABLE 406 BIOSYNEX SA: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
• TABLE 407 BIOSYNEX SA: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 408 GRIFOLS, S.A.: COMPANY OVERVIEW
• TABLE 409 GRIFOLS, S.A.: PRODUCTS OFFERED
• TABLE 410 GRIFOLS, S.A.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 411 EXAGEN INC.: COMPANY OVERVIEW
• TABLE 412 EXAGEN INC.: PRODUCTS OFFERED
• TABLE 413 EXAGEN INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 414 ARK DIAGNOSTICS, INC.: COMPANY OVERVIEW
• TABLE 415 ARK DIAGNOSTICS, INC.: PRODUCTS OFFERED
• TABLE 416 R-BIOPHARM AG: COMPANY OVERVIEW
• TABLE 417 R-BIOPHARM AG: PRODUCTS OFFERED
• TABLE 418 R-BIOPHARM AG: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
• TABLE 419 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW
• TABLE 420 RANDOX LABORATORIES LTD.: PRODUCTS OFFERED
• TABLE 421 APDIA GROUP: COMPANY OVERVIEW
• TABLE 422 BBI SOLUTIONS: COMPANY OVERVIEW
• TABLE 423 EAGLE BIOSCIENCES, INC.: COMPANY OVERVIEW
• TABLE 424 JASEM LABORATORY SYSTEMS AND SOLUTIONS: COMPANY OVERVIEW
• TABLE 425 AALTO SCIENTIFIC, LTD.: COMPANY OVERVIEW
• TABLE 426 IMMUNDIAGNOSTIK AG: COMPANY OVERVIEW
• TABLE 427 UTAK: COMPANY OVERVIEW
• TABLE 428 SEKISUI MEDICAL CO., LTD.: COMPANY OVERVIEW
• TABLE 429 DIASYSTEM SCANDINAVIA AB: COMPANY OVERVIEW
• TABLE 430 CAMBRIDGE LIFE SCIENCES LIMITED: COMPANY OVERVIEW
• TABLE 431 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: COMPANY OVERVIEW
• TABLE 432 BUHLMANN LABORATORIES AG: COMPANY OVERVIEW
• TABLE 433 SJK GLOBAL, LLC: COMPANY OVERVIEW
• TABLE 434 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
• TABLE 435 QED BIOSCIENCE INC.: COMPANY OVERVIEW
• TABLE 436 BODITECH MED INC.: COMPANY OVERVIEW
• TABLE 437 IMMUNODIAGNOSTIC SYSTEMS: COMPANY OVERVIEW

List of Figures

• FIGURE 1 THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION
• FIGURE 2 THERAPEUTIC DRUG MONITORING MARKET: RESEARCH DESIGN
• FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
• FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
• FIGURE 6 ESTIMATING GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS
• FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 8 TOP-DOWN APPROACH
• FIGURE 9 DATA TRIANGULATION
• FIGURE 10 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
• FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
• FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THERAPEUTIC DRUG MONITORING MARKET
• FIGURE 17 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE MARKET
• FIGURE 18 ANTIEPILEPTIC DRUGS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
• FIGURE 19 CHINA TO REGISTER HIGHEST GROWTH FROM 2024 TO 2029
• FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
• FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
• FIGURE 22 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 23 UK: NUMBER OF DECEASED DONORS AND TRANSPLANTS, APRIL 1, 2020-MARCH 31, 2024
• FIGURE 24 PERSONALIZED MEDICINE APPROVALS BY US FDA, 2015-2022
• FIGURE 25 NUMBER OF RESEARCH PUBLICATIONS ON THERAPEUTIC DRUG MONITORING, 2015-2021
• FIGURE 26 INCIDENCE OF DIABETES, BY REGION, 2021 VS. 2030 VS. 2045 (MILLION)
• FIGURE 27 NUMBER OF US ADULTS WITH ACTIVE EPILEPSY, BY AGE GROUP (THOUSAND)
• FIGURE 28 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2045 (MILLION)
• FIGURE 29 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2014-2021
• FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
• FIGURE 31 DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES
• FIGURE 32 THERAPEUTIC DRUG MONITORING MARKET: ECOSYSTEM ANALYSIS
• FIGURE 33 PATENT ANALYSIS FOR THERAPEUTIC DRUG MONITORING, JANUARY 2015-DECEMBER 2023
• FIGURE 34 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING
• FIGURE 35 THERAPEUTIC DRUG MONITORING MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
• FIGURE 37 KEY BUYING CRITERIA FOR END USERS
• FIGURE 38 INVESTMENT AND FUNDING SCENARIO
• FIGURE 39 US: PATIENTS ON WAITING LIST VS. TRANSPLANTS PERFORMED, BY ORGAN, 2023
• FIGURE 40 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
• FIGURE 41 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
• FIGURE 42 THERAPEUTIC DRUG MONITORING MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD BILLION)
• FIGURE 43 THERAPEUTIC DRUG MONITORING MARKET SHARE ANALYSIS, 2023
• FIGURE 44 THERAPEUTIC DRUG MONITORING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 45 THERAPEUTIC DRUG MONITORING MARKET: COMPANY FOOTPRINT
• FIGURE 46 THERAPEUTIC DRUG MONITORING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 47 EV/EBITDA OF KEY VENDORS
• FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 49 THERAPEUTIC DRUG MONITORING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2023)
• FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
• FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
• FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
• FIGURE 54 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
• FIGURE 55 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2023)
• FIGURE 56 BIOMERIEUX SA: COMPANY SNAPSHOT (2023)
• FIGURE 57 BIOSYNEX SA: COMPANY SNAPSHOT (2023)
• FIGURE 58 GRIFOLS, S.A.: COMPANY SNAPSHOT (2023)
• FIGURE 59 EXAGEN INC.: COMPANY SNAPSHOT (2023)